3-fluoro-4-[[4-(1H-indazol-5-yl)-6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2-yl]oxy]-N,N-dimethylbenzamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-fluoro-4-[[4-(1H-indazol-5-yl)-6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2-yl]oxy]-N,N-dimethylbenzamide
• 化学式: C₂₅H₂₄FN₇O₃
• 分子量: 489.5
• InChiKey: ZJYMAGNZGTVTKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• NOVEL TRIAZINE COMPOUNDS
  申请人：Sphaera Pharma Pte. Ltd.

  公开号：US20150197515A1

  公开（公告）日：2015-07-16

  The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical acceptable excipients and use of the compounds to modulate the PI3K/mTOR pathway.

  本发明涉及一种新的三嗪化合物，其化学式为（1）。本发明还揭示了化学式I的化合物，以及其他药用可接受的辅料和使用这些化合物来调节PI3K/mTOR通路的方法。
• [EN] NOVEL TRIAZINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE TRIAZINE
  申请人：SPHAERA PHARMA PTE LTD

  公开号：WO2014016849A9

  公开（公告）日：2014-03-13
• TRIAZINE COMPOUND HAVING PI3K-ALPHA AND MTOR INHIBITING ACTIVITY
  申请人：Sphaera Pharma Pte. Ltd

  公开号：EP2874632B1

  公开（公告）日：2020-06-17
• FUNCTION HOMOLOGY SCREENING
  申请人：Berg L. Ellen

  公开号：US20080070271A1

  公开（公告）日：2008-03-20

  A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.
• US9630958B2
  申请人：——

  公开号：US9630958B2

  公开（公告）日：2017-04-25